News coverage about Halozyme Therapeutics (NASDAQ:HALO) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.0662467085198 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Beh – KSWO 7News | Breaking News, Weather and Sports (kswo.com)
- This News Explains Halozyme Therapeutics' Double-Digit Drop Today (finance.yahoo.com)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. – HALO (finance.yahoo.com)
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO) (finance.yahoo.com)
- This News Explains Halozyme Therapeutics’ Double-Digit Drop Today (fool.com)
Shares of Halozyme Therapeutics (NASDAQ HALO) traded down $0.62 during trading hours on Wednesday, hitting $19.74. 1,009,400 shares of the stock were exchanged, compared to its average volume of 1,135,820. Halozyme Therapeutics has a 1-year low of $10.74 and a 1-year high of $21.13. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. The stock has a market capitalization of $2,550.00, a PE ratio of -29.03 and a beta of 2.09.
A number of brokerages recently weighed in on HALO. Piper Jaffray Companies boosted their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 16th. BidaskClub cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. BMO Capital Markets boosted their price target on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a research report on Wednesday, November 8th. Barclays cut shares of Halozyme Therapeutics from an “overweight” rating to a “hold” rating and boosted their price target for the company from $16.00 to $19.00 in a research report on Wednesday, November 22nd. Finally, Zacks Investment Research cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, December 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.14.
ILLEGAL ACTIVITY NOTICE: “Halozyme Therapeutics (NASDAQ:HALO) Getting Somewhat Positive Press Coverage, Study Shows” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/01/17/halozyme-therapeutics-halo-receiving-somewhat-favorable-news-coverage-report-shows.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.